drughunter.com
Mar. 14, 2023

Ziftomenib: 2022 MOTY Nominee

Kura Oncology menin-MLL1 inhibitor

oral, QD menin-MLL1 inhibitor Ph. I/II for leukemia from HTS and SBDD ziftomenib (KO-539) Kura Oncology, San Diego, CA / UMich (Grembecka Lab)

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in